Navigation Links
Legume compounds may help cancer treatment

The ARC Centre of Excellence for Integrative Legume Research (CILR) has lodged a complete patent application for compounds to treat cancer.

CILR researchers screened legumes (plants which obtain useable nitrogen from soil bacteria in their roots) for biological activity and they identified a number of compounds which could potentially prevent the formation of a blood supply to tumours. Without an adequate blood supply tumours stop growing and ultimately can regress.

The research has attracted major international interest for intensive collaboration and joint development.

The discovery has resulted in a formal research collaboration which is currently underway with French "CSIRO-equivalent" Centre National de la Recherche Scientifique. Co-investment discussions are also in progress with a New Zealand company.

The CILR formed a commercialisation business "Meristomics" last October to commercialise plant research discoveries. CILR's partner universities (the University of Queensland, Australian National University, University of Newcastle and University of Melbourne) passed on their commercialisation rights to Uniquest Pty Ltd, the University of Queensland's main commercialisation company.

Meristomics Chief Executive Officer Ian Harris said successful completion of this patent demonstrated that Meristomics was an effective model for commercialisation involving multiple partner universities.

"Through UniQuest, Meristomics had immediate access to substantial commercial expertise and is looking to build on its patent success by attracting further funding to progress the research," Mr Harris said.

The anti-cancer molecules are produced by legumes during the early symbiotic relationship with soil bacteria known as rhizobia. Rhizobia induce legumes to form tiny new root organs called "root nodules." The bacteria live in the nodules and provide the plant with useable nitrogen it can convert into proteins.

CILR Chief Investigator Professor Chris Parish's group, based at ANU's John Curtin School of Medical Research, developed the bioassay used to identify the compounds as potential therapeutic agents.

"We have identified several compounds derived from the legume interaction with rhizobium bacteria that show strong anti-angiogenic activity.

"They are promising therapeutic molecules which clearly warrant further investigation," Professor Parish said.

CILR Director Professor Peter Gresshoff said the current research success highlighted the importance of a critical mass of multidisciplinary biological scientists working together.

"The CILR was formed in 2003 through the Australian Research Council (ARC) Centres of Excellence scheme to create the scale and focus required to build on existing research strengths through collaboration, and to be internationally competitive.

"ARC core funding and major support through Queensland Government Smart State research funding has been vital in building capacity. It has enabled this marvellous research outcome," Professor Gresshoff said.


'"/>

Source:Research Australia


Related biology news :

1. Researchers discover chemical compounds that affect plant growth
2. Bacterial genome sheds light on synthesizing cancer-fighting compounds
3. Scientists discover the bodys marijuana-like compounds are crucial for stress-induced pain relief
4. Evolution of taste receptor may have shaped human sensitivity to toxic compounds
5. Novel compounds show promise as safer, more potent insecticides
6. Metal-containing compounds show promise as HIV weapon
7. Seaweed yields new compounds with pharmaceutical potential
8. Phenolic compounds may explain Mediterranean diet benefits
9. Marijuana-like compounds suppress the immune response
10. Microbes transform safest PBDEs into more harmful compounds
11. Harvard scientists identify compounds that stimulate stem cell growth in the brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... ivWatch LLC , a medical device company focused on improving the ... its ISO 13485 Certification, the global standard for medical device quality ... ... device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
Breaking Biology Technology: